What to do with bad PBSC mobilizers?
|
|
- Cody Chandler
- 7 years ago
- Views:
Transcription
1 What to do with bad PBSC mobilizers? Rafael F. Duarte Director Programa de Trasplante Jefe Sección de Onco-Hematología
2 Are poor mobilizers a real problem? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor for Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies in poor mobilizers
3 Are poor mobilizers a real problem? Is there a need for improvement? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor for Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies in poor mobilizers
4 What s a poor mobilizer? Poor or failed mobilization is often defined as a collection of <2 x 10 6 cells/kg 1,2 Factors associated with poor PBSC mobilization Patient age >60 years 3 Underlying disease 2,3 Previous RT and chemotherapy 1-3 Novel induction strategies may adversely affect mobilization Lenalidomide results in a significantly lower yield of CD34+ cells (P<0.001) and increased number of apheresis collections required (P<0.004) 4,5 Rituximab 6 Fludarabine 7 1. Goterris R, et al. Bone Marrow Transplant. 2005;36(10): Micallef IN, et al. Hematol J. 2000;1(6): Stiff PJ. Bone Marrow Transplant. 1999;23(suppl 2):S29-S Kumar S, et al. Leukemia. 2007;21(9): Mazumder A, et al. Leukemia. 2008;22; Benekli M et al. Bone Marrow Transplant. 2003;32(2): Herbert KE, et al. Leukemia 2009;23(2):
5 What are the consequences of suboptimal mobilization? Failure to mobilize a sufficient number of CD34+ cells may result in: Increased number of days of apheresis Need for bone marrow harvest Ineligibility for transplantation Additional burden on patients Use of sub-optimal apheresis product may lead to Delayed, partial, or failed stem cell engraftment 1 Increased need for transfusions 2 1. Haas R, et al. Blood 1994; 2. Schiller G, et al. Blood 1995
6 No major innovations in this area for a long time A small number of stem cells are found in peripheral blood during homeostasis 1 Chemomobilized PBSCs are first used in auto-hsct; PBSCs then become a widely used alternative to bone marrow 3 Mobilization with growth factor alone or growth factor plus chemotherapy becomes standard in clinical practice 7, and beyond An increased number of stem cells are observed in the peripheral blood following chemotherapy 2 GM-CSF 4 and G-CSF 5 mobilize high numbers of PBSCs (1988) and begin to be used in auto-hsct 6 Novel strategies 1. Goodman JW and Hodgson GS. Blood. 1962;19: Richman CM, et al. Blood. 1976;74(6): Kessinger A, et al. Blood. 1988;71(3): Socinski MA, et al. Lancet. 1988;1(8596): Duhrsen U, et al. Blood. 1988;72(6): Gianni AM, et al. Lancet. 1989;2(8663): Bensinger W, et al. J Clin Oncol. 1995;13(10): Tricot G, et al. Blood. 1995;85(2):
7 Are poor mobilizers a real problem? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor for Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies in poor mobilizers
8 Mozobil (plerixafor injection) A bicyclam molecule 1 Reversibly binds to CXCR4 receptor and blocks SDF-1 interaction 2 Very water-soluble 1 Highly charged 3 Low molecular weight (MW = 502) 1 Rapidly increases mobilization of CD34+ hematopoietic stem cells 1
9 Are poor mobilizers a real problem? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor for Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies in poor mobilizers
10 Plerixafor Phase III Registration Trials in MM and NHL NHL patients 1 (Study 1) n = 298 R G-CSF (10 micrograms/kg/day) + plerixafor (0.24 mg/kg) G-CSF (10 micrograms/kg/day) + placebo MM patients 2 (Study 2) n = 302 R G-CSF (10 micrograms/kg/day) + plerixafor (0.24 mg/kg) G-CSF (10 micrograms/kg/day) + placebo 1) DiPersio et al. J Clin Oncol. 2009;27(28): ; 2) DiPersio et al. Blood 2009;113:
11 Median PB CD34+ cell count (cells/µl) WHAT TO DO WITH POOR PERIPHERAL BLOOD STEM CELL MOBILIZERS? Plerixafor Phase III Registration Trials in MM and NHL PB CD34+ Cell Levels with G-CSF + Plerixafor Placebo + G-CSF Plerixafor + G-CSF (p < 0.001) 4.8-fold (p < 0.001) 5.0-fold 1.7-fold 1.4-fold Day 4 Day 5 Day 4 Day 5 Study 1 (NHL) 1 Study 2 (MM) 2
12 Plerixafor Phase III Registration Trials in MM and NHL Efficacy and Safety in Optimal Conditions Evidence of Limited Utility in our Clinical Context FDA Approval EMA Approval
13 Are poor mobilizers a real problem? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor for Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies in poor mobilizers
14 Plerixafor Failed Placebo Cases in the Registration Trials Multiple Myeloma Non-Hodgkin s Lymphoma Placebo + G-CSF n = 154 Placebo + G-CSF n = entered rescue 100% achieved cells/kg 100% underwent transplant 57% underwent tandem transplant 52 entered rescue 63.5% achieved cells/kg 13.5% achieved cells/kg 88% underwent transplant
15 Success Rate (%) WHAT TO DO WITH POOR PERIPHERAL BLOOD STEM CELL MOBILIZERS? Plerixafor American Compassionate Use Program 66% of cases collected CD34+ Cells/kg Comparison by Disease Type G. Calandra, et al. BMT % 76% 71% N=63 N=17 N=35
16 Plerixafor European Compassionate Use Program R. Duarte, et al. European Consortium on Stem Cell Mobilization
17 Plerixafor European Compassionate Use Program MOBILIZATION SUCCESS ECOSM Communications on Plerixafor at EBMT 2011 Abstract Yield of Presenting CD34/kg Authors Focus 3.1 x10^6/kg on Primary Endpoint P 1073 I.H. Gabriel, et al. 528 (75%) >2 x10^6/kg Elderly patients P 1075 K. Hübel, et al. Lymphoma subtypes (Hodgkin ) P 1077 G. Basak, et al. Overweight/Obesity P 1083 O. Jaksic, et al. Apheresis volume P 1100 Z. Koristek, et al. Paediatric patients P 1202 N. Worel, et al. Non-haematological indications O 377 R.F. Duarte, et al. Multivariate analysis of the series chemo-based vs steady-state, previous AutoHCT, new chemo agents (e.g. lenalidomide, fludarabine, etc), 1
18 Plerixafor European Compassionate Use Program Disease Subtypes p= MM NHL HL Other
19 Plerixafor European Compassionate Use Program Baseline Platelet Count p= PLAT< PLAT>100
20 Plerixafor European Compassionate Use Program Prior Chemotherapy Lines p= <4 Lines 4 Lines
21 Plerixafor European Compassionate Use Program Prior Agents p= p= p= Lena No Lena Fluda No Fluda RadioTh No RadioTh
22 Plerixafor European Compassionate Use Program Steady-state vs Chemo-based p= Steady-State Chemo-based
23 Plerixafor European Compassionate Use Program MULTIVARIATE ANALYSIS OF FACTORS INFLUENCING MOBILIZATION SUCCESS Underlying Disease (NHL vs others) <0.001; OR: 2.54 ( ) Prior lines of Tx (>3 lines) <0.001; OR: 2.24 ( ) Trombocytopenia (<100) 0.008; OR: 2.54 ( )
24 Plerixafor European Compassionate Use Program Age Sex UNIVARIATE ANALYSIS OF FACTORS INFLUENCING MOBILIZATION SUCCESS n.s. n.s. Underlying Disease <0.001 Prior lines of Treatment Prior Fludarabine Prior Lenalidomide Prior Melphalan Prior Radiotherapy n.s. n.s. n.s. Prior Mobilization Attempts 0.04 Prior chemo vs GCSF n.s. Platelets < Other cytopenias n.s.
25 Current Mobilization Strategies: Is there a need for improvement? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor in Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies and Algorithms
26 Efficient Algorithms and Strategies using Plerixafor
27 Efficient Algorithms and Strategies using Plerixafor I.N.M. Micallef; Rochester, MN Based on CD34 targets Does not base decisions on clinical risk factors They monitor CD34 levels in PB on days 4 and 5 of steady state GCSF mobilization (chemo excluded), and patients get plerixafor on day 5 if low CD34 (<10) or 1 st day collection <0.5 x10 6 /kg S.H. Abhyankar; Kansas, KS Based on CD34 targets and some risk factors CD34 levels on day 5: <10 if target 2.5 x10 6 /kg; <20 if target 5 x10 6 /kg CD34 collected on 1 st day < half the desired target (2.5 or 5 x10 6 /kg) Lenalidomide (>4), delayed count recovery, other reasons, treated upfront on day 4 J. Shapiro; Tampa, FL Based on Risk Factors and/or CD34 targets High risk patients, based on the following criteria, are treated upfront with plerixafor on day 4: Received 3 lines of chemotherapy Received 2 lines of chemotherapy plus a radioimmunoconjugate (Zevalin or Bexxar ) Received 2 lines of chemotherapy plus radiation to extensive fields (mantle, craniospinal, pelvis) Received 4 or more courses of HyperCVAD or more than 4 cycles of lenalidomide Hypocellular marrow (defined as 25% cellularity) Platelet count < 1 x 10 5 /µl in the absence of chemotherapy within the last 3 week Previous failure to collect after G-CSF or chemotherapy priming Standard Risk patients (others), get plerixafor on day 5 if low CD34 (<10) or 1 st day collection
28 Efficient Algorithms and Strategies using Plerixafor I.N.M. Micallef; Rochester, MN Based on CD34 targets Change from Plerixafor-1 (day 5) to Plerixafor-2 (day 4)
29 Efficient Algorithms and Strategies using Plerixafor L.J. Costa; Charleston, SC Based on CD34 levels on day 4 Establishes correlation between day 4 PB CD34 levels and GCSF-mobilized CD34 target collected Pros: 1) Predictability, regardless of risk factors, 2) Better utilization apheresis resources, 3) apheresis performed on the right day Cons: 1) Underestimates impact of plerixafor if very low CD34 levels on day 4, 2) algorithm could vary from center to center multicenter validation (???)
30 Plerixafor: Experience at ICO & BST CD34+ <10/µL in PB on day 4: 105 consecutive Myeloma and Lymphoma patients with of G- CSF mobilization for Auto-HCT. I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
31 Plerixafor: Experience at ICO & BST P <0.001 I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
32 Plerixafor: Experience at ICO & BST P <0.001 I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
33 Plerixafor: Experience at ICO & BST P <0.001 I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
34 Plerixafor: Experience at ICO & BST P <0.001 for all comparisons I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
35 Plerixafor: Experience at ICO & BST 1! 2! 3! 4! 5! 6! 7! Table 4. Plerixafor use as a remobilization versus preemptive strategy.! PB CD34+ count on Day 4, cells/µl Mean (s.d.) Min-Max PB CD34+ count on Day 5, cells/µl Mean (s.d.) Min-Max Fold-expansion Day 4 to Day 5 Mean (s.d.) Min-Max Collection 2 CD34+ cells x10 6 /kg, n (%) Overall First apheresis only CD34+ yield, cell count x10 6 /kg Overall Mean (s.d.) Min-Max First apheresis only Mean (s.d.) Min-Max Doses of plerixafor* Mean (s.d.) Min-Max Remobilization (n=25) 3.7 (2.3) (13.4) (3.14) /25 (64%) 11/25 (44%) 2.44 (1.46) (1.55) (0.59) 1-3 Preemptive (n=13) 4.9 (2.3) (9.8) (2.39) /13 (92%) 11/13 (85%) 3.73 (1.63) (1.79) (0.28) 1-2 P * Doses of plerixafor (i.e. days of plerixafor treatment) administered with an intention to reach the primary endpoint to collect 2/kg CD34+ cells, including 33 doses in 28 patients who met the target and 17 doses administered to 10 patients who did not. 8!! I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
36 Plerixafor: Experience at ICO & BST 1! 2! 3! 4! 5! 6! 7! Table 4. Plerixafor use as a remobilization versus preemptive strategy.! PB CD34+ count on Day 4, cells/µl Mean (s.d.) Min-Max PB CD34+ count on Day 5, cells/µl Mean (s.d.) Min-Max Fold-expansion Day 4 to Day 5 Mean (s.d.) Min-Max Collection 2 CD34+ cells x10 6 /kg, n (%) Overall First apheresis only CD34+ yield, cell count x10 6 /kg Overall Mean (s.d.) Min-Max First apheresis only Mean (s.d.) Min-Max Doses of plerixafor* Mean (s.d.) Min-Max Remobilization (n=25) 3.7 (2.3) (13.4) (3.14) /25 (64%) 11/25 (44%) 2.44 (1.46) (1.55) (0.59) 1-3 Preemptive (n=13) 4.9 (2.3) (9.8) (2.39) /13 (92%) 11/13 (85%) 3.73 (1.63) (1.79) (0.28) 1-2 P * Doses of plerixafor (i.e. days of plerixafor treatment) administered with an intention to reach the primary endpoint to collect 2/kg CD34+ cells, including 33 doses in 28 patients who met the target and 17 doses administered to 10 patients who did not. 8!! I Sánchez-Ortega, et al. Bone Marrow Transplant 2015 Jan; 50(1):
37 Current Mobilization Strategies: Is there a need for improvement? Plerixafor, Mozobil Product characteristics Efficacy data in the Phase III Registration Clinical Trials Plerixafor in Poor Mobilizers Efficiency requires additional evidence From the available evidence to Efficient Mobilization Strategies and Algorithms
38 What to do with bad PBSC mobilizers? Rafael F. Duarte Director Programa de Trasplante Jefe Sección de Onco-Hematología
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development
More informationRunning head: Body mass index affects stem cell yield
Donor body mass index is an important factor that affects peripheral blood stem cell yield in healthy donors after mobilization with granulocyte-colony stimulating factor Running head: Body mass index
More informationPeripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells
Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When Objectives Why do need stem cell transplants What type of cells are we using for stem cell transplants When and how we collect peripheral
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationImmunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More information-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationJennifer G. Collins, RN Children s Hospital of Chicago
Jennifer G. Collins, RN Children s Hospital of Chicago Review the importance of consultation with the stem cell transplant team Review criteria to begin harvest Review ways to modify a harvest procedure
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationHenk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationSEARCHING FOR A BONE MARROW DONOR
SEARCHING FOR A BONE MARROW DONOR Angela received a bone marrow transplant from an unrelated donor to treat her non-hodgkin s lymphoma. INFORMATION FOR PATIENTS AND THEIR FAMILIES For patients who need
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationLymphoma. Starting Point. Diagnosed with Lymphoma?
ESSENTIALS Lymphoma Diagnosed with Lymphoma? It s important to understand everything you can about your diagnosis, treatment options, and places to go for support. This will help you make treatment decisions
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationMyeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants
Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationMultiple Myeloma High-Dose Chemotherapy and Stem Cell Transplantation
Multiple Myeloma High-Dose Chemotherapy and Stem Cell Transplantation 1 About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF) was founded in 1998 by identical twin
More informationTITLE: Plerixafor for Patients Failing Stem Cell Mobilization: Clinical and Cost- Effectiveness and Guidelines
TITLE: Plerixafor for Patients Failing Stem Cell Mobilization: Clinical and Cost- Effectiveness and Guidelines DATE: 19 November 2015 RESEARCH QUESTIONS 1. What is the clinical effectiveness of plerixafor
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationSTUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan
STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationChemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015
Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive
More informationBilling Information for MOZOBIL (plerixafor injection)
Billing Information for MOZOBIL (plerixafor injection) This guide is intended solely for educational purposes and, specifically, to assist hospital and physician office billing staff with reimbursement
More informationBlood and Marrow Stem Cell Transplantation
Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationNorthside Hospital Blood & Marrow Transplant Program
Northside Hospital Blood & Marrow Transplant Program The Blood & Marrow Transplant roup O F G E O R G I A F O C U S O N T H E PAT I E N T S C O M PA S S I O N AT E C A R E S TAT E - O F - T H E - A R T
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationFresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport
Cytotherapy (2006) Vol. 8, No. 2, 158/165 Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport V Antonenas 1, F Garvin 1, M Webb 1, M Sartor 2,
More informationguides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research
infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationRADIATION THERAPY FOR LYMPHOMA. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY
RADIATION THERAPY FOR Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT The lymphatic system is a network of tiny vessels extending
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationstorage and handling of unused stem cell products Swiss consensus?
storage and handling of unused stem cell products Swiss consensus? 16. Jan. 2015 Panagiotis Samaras, Mario Bargetzi stored units USZ Type of unused product autologous stem cells never transplanted 2nd
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationGraft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationDisclosures for Elena Zamagni
Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients receiving upfront autologous stem-cell transplantation: a prospective study Zamagni E. 1, Nanni C. 2, Patriarca F. 3,
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, MD Director, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu A 40-year old man with acute myelogenous
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationEnumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood
Application Note Primary Cell Analysis Enumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood Cell Viability Introduction: Bone Marrow, Cord Blood, Stem
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationDonating Life. The Workplace Partnership for Life Program
The Workplace Partnership for Life Program Every day about 63 people receive an organ transplant, but another 16 people on the waiting list die because not enough organs are available. Approximately 80,000
More informationHematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:
More informationHematologic Malignancies
C O N N E C T I N G L I F E A N D S C I E N C E Hematologic Malignancies Issue Number 7 Spring 2010 Myelodysplastic Syndromes Peter Westervelt, M.D., Ph.D., Associate Professor of Medicine Chief, Section
More informationDonating stem cells. What s involved?
Donating stem cells What s involved? Revised February 2012 The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More information